title: The optimal dosing of gemtuzumab ozagamicin: where to go from here?
authors.affiliation: Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, the Netherlands theo.dewitte@radboudumc.nl.
authors.forename: Theo
authors.initials: T
authors.lastname: de Witte
authors.affiliation: Tor Vergata University Hospital, Rome, Italy.
authors.forename: Sergio
authors.initials: S
authors.lastname: Amadori
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000617:Aminoglycosides / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D000079982:Gemtuzumab; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*
chemical_list: D000617:Aminoglycosides; D061067:Antibodies, Monoclonal, Humanized; D000079982:Gemtuzumab